000			02224 a2200625 4500
005			20250515165327.0
264		0	_c20110719
008			201107s 0 0 eng d
022			_a1558-1497
024	7		_a10.1016/j.neurobiolaging.2009.03.004 _2doi
040			_aNLM _beng _cNLM
100	1		_aShan, Sun
245	0	0	_aNew evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. _h[electronic resource]
260			_bNeurobiology of aging _cMar 2011
300			_a443-58 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_a1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine _xadverse effects
650	0	4	_aAnalysis of Variance
650	0	4	_aAnimals
650	0	4	_aAntibodies _xpharmacology
650	0	4	_aAntiparkinson Agents _xpharmacology
650	0	4	_aApomorphine _xpharmacology
650	0	4	_aChemokine CX3CL1 _xadverse effects
650	0	4	_aDNA Nucleotidylexotransferase _xpharmacology
650	0	4	_aDisease Models, Animal
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Interactions
650	0	4	_aGene Expression Regulation _xdrug effects
650	0	4	_aLevodopa _xpharmacology
650	0	4	_aMale
650	0	4	_aMental Disorders _xetiology
650	0	4	_aNerve Tissue Proteins _xmetabolism
650	0	4	_aParkinson Disease _xcomplications
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aReaction Time _xdrug effects
650	0	4	_aStereotyped Behavior _xdrug effects
650	0	4	_aSubstantia Nigra _xmetabolism
650	0	4	_aTyrosine 3-Monooxygenase _xmetabolism
700	1		_aHong-Min, Tang
700	1		_aYi, Feng
700	1		_aJun-Peng, Gao
700	1		_aYue, Fan
700	1		_aYan-Hong, Tang
700	1		_aYun-Ke, Yang
700	1		_aWen-Wei, Li
700	1		_aXiang-Yu, Wang
700	1		_aJun, Ma
700	1		_aGuo-Hua, Wang
700	1		_aYa-Ling, Huang
700	1		_aHua-Wei, Li
700	1		_aDing-Fang, Cai
773	0		_tNeurobiology of aging _gvol. 32 _gno. 3 _gp. 443-58
856	4	0	_uhttps://doi.org/10.1016/j.neurobiolaging.2009.03.004 _zAvailable from publisher's website
999			_c18801032 _d18801032